The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Carrier effects on biological activity of amphotericin B
Open accessAbstract
Amphotericin B (AmB), the drug of choice for the treatment of most systemic fungal infections, is marketed under the trademark Fungizone, as an AmB-deoxycholate complex suitable for intravenous administration. The association between AmB and deoxycholate is relatively weak; therefore, dissociation occurs in the blood. The drug itself interacts with both mammalian and fungal cell membranes to damage cells, but the greater susceptibility of fungal cells to its effects forms the basis for its clinical usefulness. The ability of the drug to form stable complexes with lipids has allowed the development of new formulations of AmB based on this property. Several lipid-based formulations of the drug which are more selective in damaging fungal or parasitic cells than mammalian cells and some of which also have a better therapeutic index than Fungizone have been developed. In vitro investigations have led to the conclusion that the increase in selectivity observed is due to the selective transfer of AmB from lipid complexes to fungal cells or to the higher thermodynamic stability of lipid formulations. Association with lipids modulates AmB binding to lipoproteins in vivo, thus influencing tissue distribution and toxicity. For example, lipid complexes of AmB can be internalized by macrophages, and the macrophages then serve as a reservoir for the drug. Furthermore, stable AmB-lipid complexes are much less toxic to the host than Fungizone and can therefore be administered in higher doses. Experimentally, the efficacy of AmB-lipid formulations compared with Fungizone depends on the animal model used. Improved therapeutic indices for AmB-lipid formations have been demonstrated in clinical trials, but the definitive trials leading to the selection of an optimal formulation and therapeutic regimen have not been done.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amphotericin B: 30 Years of Clinical Experience
Gallis, H. A., Drew, R. H., & Pickard, W. W. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.2.308 · Cited by 1,009
How do the polyene macrolide antibiotics affect the cellular membrane properties?
Bolard, J. (1986) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/0304-4157(86)90002-x · Cited by 750
Self-citationAmphotericin B: current understanding of mechanisms of action
Brajtburg, J., Powderly, W. G., Kobayashi, G. S., & Medoff, G. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.2.183 · Cited by 504
Self-citationRecent Trends in the Discovery, Development, and Evaluation of Antifungal Agents
Fromtling, R. A., Braun, P. C., & Hector, R. (1987) · DigitalCommons - Fairfield (Fairfield University) · Cited by 474
Lopez-Berestein, G., Fainstein, V., Hopfer, R., Mehta, K., Sullivan, M. P., Keating, M., Rosenblum, M. G., Mehta, R., Luna, M., Hersh, E. M., et al. (1985) · Journal of Infectious Diseases · doi:10.1093/infdis/151.4.704 · Cited by 405
Lopez-Berestein, G., Mehta, R., Hopfer, R. L., Mills, K., Kasi, L., Mehta, K., Fainstein, V., Luna, M., Hersh, E. M., & Juliano, R. (1983) · Journal of Infectious Diseases · doi:10.1093/infdis/147.5.939 · Cited by 303
Liposomal and Lipid Formulations of Amphotericin B: Clinical Pharmacokinetics
Janknegt, R., de Marie, S., Bakker-Woudenberg, I. A. J. M., & Crommelin, D. J. A. (1992) · Clinical Pharmacokinetics · doi:10.2165/00003088-199223040-00004 · Cited by 274
Bolard, J., Legrand, P., Heitz, F., & Cybulska, B. (1991) · Biochemistry · doi:10.1021/bi00237a011 · Cited by 268
Self-citationAdler-moore, J. P., & Proffitt, R. T. (1993) · Journal of Liposome Research · doi:10.3109/08982109309150729 · Cited by 251
Amphotericin B-resistant yeast infection in severely immunocompromised patients
Powderly, W. G., Kobayashi, G. S., Herzig, G. P., & Medoff, G. (1988) · The American Journal of Medicine · doi:10.1016/0002-9343(88)90059-9 · Cited by 232
Cited by
Aspergillus fumigatus and Aspergillosis
Latgé, J.-P. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.2.310 · Cited by 2,307
Amphotericin B: side effects and toxicity
Laniado-Laborín, R., & Cabrales-Vargas, M. N. (2009) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2009.06.003 · Cited by 739
Targeted Delivery of Amphotericin B to Cells by Using Functionalized Carbon Nanotubes
Wu, W., Wieckowski, S., Pastorin, G., Benincasa, M., Klumpp, C., Briand, J., Gennaro, R., Prato, M., & Bianco, A. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200501613 · Cited by 644
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389
Cavassin, F. B., Baú-Carneiro, J. L., Vilas-Boas, R. R., & Queiroz-Telles, F. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-020-00382-7 · Cited by 382
Groll, A. H., Giri, N., Petraitis, V., Petraitiene, R., Candelario, M., Bacher, J. S., Piscitelli, S. C., & Walsh, T. J. (2000) · The Journal of Infectious Diseases · doi:10.1086/315643 · Cited by 373
Leenders, A. C. A. P., Daenen, S., Jansen, R. L. H., Hop, W. C. J., Lowenberg, B., Wijermans, P. W., Cornelissen, J., Herbrecht, R., Lelie, H. V. D., Hoogsteden, H. C., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00944.x · Cited by 319
Amphotericin B Formulations and Drug Targeting
Torrado, J. J., Espada, R., Ballesteros, M. P., & Torrado-Santiago, S. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21179 · Cited by 299
Schmidt, T. J., Khalid, S. A., Romanha, A. J., Alves, T. M., Biavatti, M. W., Brun, R., Costa, F. B. D., de Castro, S. L., Ferreira, V. F., de Lacerda, M. V. G., et al. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712800229023 · Cited by 262
Interactions between Cationic Vesicles and Candida albicans
Campanhã, M. T. N., Mamizuka, E. M., & Carmona-Ribeiro, A. M. (2001) · The Journal of Physical Chemistry B · doi:10.1021/jp003315+ · Cited by 43
Antifungal combinations in Mucorales: A microbiological perspective
Schwarz, P., Cornely, O. A., & Dannaoui, E. (2019) · Mycoses · doi:10.1111/myc.12909 · Cited by 43
Aspergillus fumigatus and Aspergillosis
(2008) · doi:10.1128/9781555815523 · Cited by 31
Metadata
- Authors
- Brajtburg, J., & Bolard, J.
- Venue
- Clinical Microbiology Reviews
- Publisher
- American Society for Microbiology
- Published
- 1996-10
- Volume
- 9
- Issue
- 4
- Pages
- 512-531
- ISSN
- 0893-8512 (ISSN-L)
- 1098-6618
- OpenAlex
- W2141025633
- Cited by
- 310
- References
- 114
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.